Both WHO-HAEM5 and ICC have recognized SF3B1 mutation and bi-allelic TP53 mutation as defining new MDS subtypes, while retaining isolated del(5q) as a specific MDS subtype. Here, TP53 is linked to myelodysplastic syndrome.